ArticleLab on a chip2017
Characterisation of anticancer peptides at the single-cell level.
Article in Lab on a chip, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Melittin, A Potential Game-changer in the Fight Against Breast Cancer: A Systematic Review.Anti-cancer agents in medicinal chemistry · 2025Pooled it
- Antimicrobial and antitumor properties of anuran peptide temporin-SHf induce apoptosis in A549 lung cancer cells.Amino acids · 2024Article
- Designing Potent Anticancer Peptides by Aurein 1.2 Key Residues Mutation and Catenate Cell-Penetrating Peptide.Advanced pharmaceutical bulletin · 2023Article
- Droplets microfluidics platform-A tool for single cell research.Frontiers in bioengineering and biotechnology · 2023Review
- The future of microfluidics in immune checkpoint blockade.Cancer gene therapy · 2021Review
- Quantification of Protein Secretion from Circulating Tumor Cells in Microfluidic Chambers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- A Microfluidic Platform for Single Cell Fluorometric Granzyme B Profiling.Theranostics · 2020Article
- Recent advances in microfluidic platforms for single-cell analysis in cancer biology, diagnosis and therapy.Trends in analytical chemistry : TRAC · 2019Article
- Using the Bacterial Ribosome as a Discovery Platform for Peptide-Based Antibiotics.Biochemistry · 2019Review
- Single-cell protein profiling in microchambers with barcoded beads.Microsystems & nanoengineering · 2019Article
- Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs/ROS/Trx1 signalling pathway.Journal of experimental & clinical cancer research : CR · 2018Article
- Integrating Immunology and Microfluidics for Single Immune Cell Analysis.Frontiers in immunology · 2018Review
- Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The development of efficacious anticancer therapeutics is difficult due to the heterogeneity of the cellular response to chemotherapy. Anticancer peptides (ACPs) are promising drug candidates that have been shown to be active against a range of cancer cells. However, few ACP studies focus on tumour single-cell heterogeneities. In order to address this need, we developed a microfluidic device and an imaging procedure that enable the capture, monitoring, and analysis of several hundred single cells for the study of drug response. MCF-7 human breast adenocarcinoma cells were captured in hydrodynamic traps and isolated in individual microchambers of less than 100 pL volume. With pneumatic valves, different sets of microchambers were actuated to expose the cells to various drugs. Here, the effect of three membranolytic ACPs - melittin, aurein 1.2 and aurein 2.2 - was investigated by monitoring the efflux of calcein from single MCF-7 cells. The loss of membrane integrity was observed with two different strategies that allow either focusing on one cell for mechanistic studies or parallel analysis of hundreds of individual cells. In general, the device is applicable to the analysis of the effect of various drugs on a large number of different cell types. The platform will enable us in the future to determine the origin of heterogeneous responses on pharmacological substances like ACPs within cell populations by combining it with other on-chip analytical methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.